THERAVECTYS, the Paris-based, fully-integrated discovery & clinical development company specialized in lentiviral vector-based therapeutic vaccines and T-cell therapies launches a busy 2015 spring/summer congress season by presenting 4 posters at the 18th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in New Orleans, one of the largest conferences of its kind in the world.
Over the course of the next 3 days, members of the R&D and GMP manufacturing teams will be presenting 4 different posters on the company’s research and development activities related to its differentiated CAR-T cells programs, its lentiviral vectors therapeutic vaccines, as well as the operations of its newly established lentiviral vector bioproduction facility based in Paris.
Please join Dr. Bauche, CSO, with the R&D and production teams while they will be presenting a detailed review and updates during the poster session at the following dates and time:
- “Development of safer & optimized CAR-T Cells using Lentiviral vectors”, Wednesday, May 13 - 5:15-6:45 pm (stand #224)
- “A new cGMP production facility for clinical grade Lentiviral vectors in Europe”, Thursday, May 14 - 5:30-7:00 pm (stand #474)
- “Use of lentiviral vectors to develop anti-cancer immunotherapies”, Thursday, May 14 - 5:30-7:00 pm (stand #425)
- “Development of a successful lyophilization process for clinical grade lentiviral vectors”, Friday, May 15 - 5:30-7:00 pm (stand #671)
Following its presence at the ASGCT, members of THERAVECTYS R&D team can be met at the 21st Annual Meeting of the International Society for Cellular Therapy (ISCT) in Las Vegas prior to their attendance at the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place from May 29th to June 2nd in Chicago.
The company will then be present at the BIO International Convention in Philadelphia from June 15-18 where the Business Development team will actively pursue the promising ongoing discussions related to collaborative agreements.
For a complete review of all the scientific & partnering events where members of THERAVECTYS will be present, please visit the company’s web page in Our Science section, in “Congress & Publications”.
About THERAVECTYS
THERAVECTYS is a fully-integrated discovery and clinical development biotech company originating from the Pasteur Institute and a pioneer in the development of lentiviral vector vaccines and CAR T-cell therapies.
The company has optimized and industrialized next-generation methods to exploit the use of lentivectors in new therapies and has built a broad and robust intellectual property position in addition to licenses to fundamental intellectual property from institutions including Institut Pasteur and Institut Curie.
The company’s lead infectious disease lentivector vaccine has successfully completed a Phase I/II safety & immunogenicity human proof-of-concept study in HIV. THERAVECTYS lead oncology lentivector vaccine will enter clinical trials in 2015 while the company’s CAR T-cell therapies are in the preclinical stage.
Alone or with partners, THERAVECTYS plans to advance its pipeline of oncology and infectious disease therapies using the company’s integrated set of discovery, clinical development, and manufacturing capabilities specialized in lentiviral vector technologies. The company is privately-held and based in Villejuif, France.
